Stay updated with breaking news from Tirtht Patel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention Virtual
BRIDGEWATER, NJ / ACCESSWIRE / May 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in
Met primary study endpoints: good safety profile and reduction in central subfield thickness First oral therapy to demonstrate reduction in macular edema; supports potential for early disease...
HOUSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Chief Executive Officer Pietro Bersani, Chief Financial Officer Brian Hungerford and Chief
Medicus Pharma Ltd. is pleased to announce that it has published the abbreviated clinical study report from the SKNJCT-001 Phase 1 safety and tolerability study. SKNJCT-001 is an open-label,...